Journal of Clinical Oncology

Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer

L Luca F. Valle (Luca F. Valle, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, Radiation Oncology Service, Greater Los Angeles VA Healthcare System, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jeremie Calais, MD, PhD, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Department of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA, Amar U. Kishan, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA) J Jeremie Calais (Luca F. Valle, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, Radiation Oncology Service, Greater Los Angeles VA Healthcare System, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jeremie Calais, MD, PhD, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Department of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA, Amar U. Kishan, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA) A Amar U. Kishan
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 16
Published June 01, 2026
Pages 1556-1557
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (3)

L

Luca F. Valle

Luca F. Valle, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, Radiation Oncology Service, Greater Los Angeles VA Healthcare System, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jeremie Calais, MD, PhD, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Department of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA, Amar U. Kishan, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA

J

Jeremie Calais

Luca F. Valle, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, Radiation Oncology Service, Greater Los Angeles VA Healthcare System, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jeremie Calais, MD, PhD, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, Department of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA, Amar U. Kishan, MD, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA

A

Amar U. Kishan

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001